〇Hayato Muranaka1, Akio Hayashi2, Keiichi Minami3, Shunsuke Kitajima4, Susumu Kohno1, Yuuki Nishimoto1, Naoko Nagatani1, Misa Suzuki1, Lan Kulathunga1, Nobunari Sasaki5, Nobuhiro Okada1, Takashi Matsuzaka6, Hitoshi Shimano6, Hideaki Tada7, Chiaki Takahashi1
(1.Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, 2.Exploratory Research Laboratories, Minase Research Institute, Ono Pharmaceutical Co., Ltd, 3.Advanced Medical Research Laboratories, Tsukuba Research Institute, Ono Pharmaceutical Co., Ltd, 4.Department of Medical Oncology, Dana-Farber Cancer Institute, 5.Department of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, 6.Department of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba, 7.Oncology Research and Development Center, Minase Research Institute, Ono Pharmaceutical Co., Ltd)
ConBio2017